Medical Management of Headache and Facial Pain in CRS: A Systematic Review and Meta‐Analysis

Luke D. Heiland,Alejandro R. Marrero‐Gonzalez,Shaun A. Nguyen,Hannah G. Farmer,Vinay K. Rathi,Zachary M. Soler,Rodney J. Schlosser
DOI: https://doi.org/10.1002/lary.31502
IF: 2.97
2024-05-12
The Laryngoscope
Abstract:This study aims to characterize the effect of medical therapy on headache and facial pain/pressure among patients with chronic rhinosinusitis (CRS). Following a literature review, 17 studies reporting on 2269 patients were included in the meta‐analysis. Our findings suggest medical therapy significantly reduces facial pain and pressure in the CRS population. Objectives This study aims to characterize the effect of medical therapy on headache and facial pain/pressure among patients with chronic rhinosinusitis (CRS). Data Sources CINAHL, PubMed, and Scopus. Methods CINAHL, PubMed, and Scopus were searched from inception through April 10th, 2024, for English language articles reporting headache or facial pain/pressure outcomes in CRS patients. Inclusion was restricted to studies reporting results of the medical treatment of CRS in nonsurgical cohorts. Primary outcome measures included the sino‐nasal outcome test (SNOT) and the visual analogue scale (VAS). Meta‐analyses of continuous measures (mean), mean difference (Δ), and proportions (%) were conducted. Results The initial search yielded 2429 unique articles. After a full‐text review of 272 articles, 17 studies reporting outcomes for 2269 patients were included in the meta‐analysis. The mean patient age was 48.6 years (range 18.0–86.0; 95% CI: 46.5 to 50.6), among which 55.4% (95% CI: 51.5 to 59.4) were male and 82.9% (95% CI: 68.8 to 93.4) had nasal polyposis. SNOT facial pain/pressure scores improved by 1.1 points (95% CI: −1.7 to −0.5; relative reduction 40.4%) with non‐biologic therapies and 1.0 point (95% CI: −1.4 to −0.6; relative reduction 54.6%) with biologic therapies. On an 11‐point scale, VAS headaches scores improved by 1.8 units (95% CI: −3.3 to −0.3; 42.1% relative reduction) in CRSwNP patients and 1.0 unit (95% CI: −1.7 to −0.3; 54.0% relative reduction) in CRSsNP patients. Conclusions Our findings suggest medical therapy significantly reduces facial pain and pressure in the CRS population. Laryngoscope, 2024
medicine, research & experimental,otorhinolaryngology
What problem does this paper attempt to address?